Recombinant antibody production employs Chinese hamster ovary (CHO) cells due to their efficiency in expressing complex biologics. Enhancing these processes involves modifying various variables, including cell line selection, media composition, and bioreactor settings. A key goal is to amplify antibody yield while reducing production financial burd